Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0920646 (
renal ischemia
)
2,515
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ischemia is a leading cause of acute kidney injury. Kidney ischemia is associated with loss of cellular ion homeostasis; however, the pathways that underlie ion homeostasis dysfunction are poorly understood. Here, we evaluated the nonselective cation channel transient receptor potential melastatin 2 (TRPM2) in a murine model of
kidney ischemia
/reperfusion (I/R) injury. TRPM2-deficient mice were resistant to ischemic injury, as reflected by improved kidney function, reduced histologic damage, suppression of proapoptotic pathways, and reduced inflammation. Moreover, pharmacologic TRPM2 inhibition was also protective against I/R injury. TRPM2 was localized mainly in kidney proximal tubule epithelial cells, and studies in chimeric mice indicated that the effects of TRPM2 are due to expression in parenchymal cells rather than hematopoietic cells. TRPM2-deficient mice had less oxidative stress and lower levels of NADPH oxidase activity after ischemia. While
RAC1
is a component of the NADPH oxidase complex, its relation to TRPM2 and kidney ischemic injury is unknown. Following
kidney ischemia
, TRPM2 promoted
RAC1
activation, with active
RAC1
physically interacting with TRPM2 and increasing TRPM2 expression at the cell membrane. Finally, inhibition of
RAC1
reduced oxidant stress and ischemic injury in vivo. These results demonstrate that TRPM2-dependent
RAC1
activation increases oxidant stress and suggest that therapeutic approaches targeting TRPM2 and/or
RAC1
may be effective in reducing ischemic kidney injury.
...
PMID:TRPM2 mediates ischemic kidney injury and oxidant stress through RAC1. 2529 36